Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00825734
What this trial is testing

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 83
Large-scale testing (Phase 3)Active Not RecruitingNCT03315364
What this trial is testing

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Who this might be right for
Recurrent or Metastatic Breast Cancer
Daehwa Pharmaceutical Co., Ltd. 549
Not applicableEnded earlyNCT05488145
What this trial is testing

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8HER2-Negative Breast Carcinoma+1 more
Emory University 21
Not applicableUnknownNCT04683757
What this trial is testing

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Ying Wang 288
Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Early research (Phase 1)Looking for participantsNCT05504707
What this trial is testing

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 30
Not applicableLooking for participantsNCT07607119
What this trial is testing

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaStomach NeoplasmsLocally Advanced Gastric Cancer+1 more
Samsung Medical Center 53
Large-scale testing (Phase 3)Study completedNCT00703326
What this trial is testing

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 1,144
Testing effectiveness (Phase 2)Looking for participantsNCT06348134
What this trial is testing

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHER2-positive Breast CancerBreast Cancer
University of Chicago 74
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410234
What this trial is testing

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 110
Large-scale testing (Phase 3)Ended earlyNCT02340221
What this trial is testing

Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 631
Large-scale testing (Phase 3)Not Yet RecruitingNCT07393321
What this trial is testing

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 210
Not applicableStudy completedNCT04450706
What this trial is testing

Functional Precision Oncology for Metastatic Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
University of Utah 15
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT02942355
What this trial is testing

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Who this might be right for
Female Breast CarcinomaBreast Cancer
Wake Forest University Health Sciences 40
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Ended earlyNCT01281163
What this trial is testing

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Positive+4 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04115306
What this trial is testing

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Phoenix Molecular Designs 61
Next Page
507